#cartcells — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #cartcells, aggregated by home.social.
-
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11537 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11537 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11537 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11537 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11537 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11169 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11169 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11169 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11169 -
Post Doc in Cell-based Immune Therapies
University of North Carolina at Chapel HillSee the full job description on jobRxiv: https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/
#autoimmunediseases #bioengineering #cancer #cartcells #diabetes #gliomas #immunetolerance #immunoengineering #ScienceJobs #h...
https://jobrxiv.org/job/university-of-north-carolina-at-chapel-hill-27778-post-doc-in-cell-based-immune-therapies/?fsp_sid=11169 -
📢 Just out: a Frontiers research topic on innovations in #CARTcells featuring 2 IMI projects, T2Evolve & ImSAVAR! Discover:
☑️ how AI can progress CAR-T cell research
☑️ how to advance CAR-T therapy in Europe
☑️ how to improve CAR-T cell safety engineering
& more.
👉 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1504906/full#s1#EU #Health #Innovation #Research #HorizonEU #Science #Cancer
-
📢 Just out: a Frontiers research topic on innovations in #CARTcells featuring 2 IMI projects, T2Evolve & ImSAVAR! Discover:
☑️ how AI can progress CAR-T cell research
☑️ how to advance CAR-T therapy in Europe
☑️ how to improve CAR-T cell safety engineering
& more.
👉 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1504906/full#s1#EU #Health #Innovation #Research #HorizonEU #Science #Cancer
-
📢 Just out: a Frontiers research topic on innovations in #CARTcells featuring 2 IMI projects, T2Evolve & ImSAVAR! Discover:
☑️ how AI can progress CAR-T cell research
☑️ how to advance CAR-T therapy in Europe
☑️ how to improve CAR-T cell safety engineering
& more.
👉 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1504906/full#s1#EU #Health #Innovation #Research #HorizonEU #Science #Cancer
-
📢 Just out: a Frontiers research topic on innovations in #CARTcells featuring 2 IMI projects, T2Evolve & ImSAVAR! Discover:
☑️ how AI can progress CAR-T cell research
☑️ how to advance CAR-T therapy in Europe
☑️ how to improve CAR-T cell safety engineering
& more.
👉 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1504906/full#s1#EU #Health #Innovation #Research #HorizonEU #Science #Cancer
-
📢 Just out: a Frontiers research topic on innovations in #CARTcells featuring 2 IMI projects, T2Evolve & ImSAVAR! Discover:
☑️ how AI can progress CAR-T cell research
☑️ how to advance CAR-T therapy in Europe
☑️ how to improve CAR-T cell safety engineering
& more.
👉 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1504906/full#s1#EU #Health #Innovation #Research #HorizonEU #Science #Cancer
-
Last night, the inaugural Broermann Medical Innovation Award honored Dr. Carl June & Dr. Michel Sadelain for their pioneering work in CAR-T cell therapy.
At the Hessian State Chancellery in Wiesbaden, the award was presented by Hessian Minister Boris Rhein.
-
Scientists re-engineer a patient’s own T cells to target and destroy cancer cells
Hodgkin lymphoma and other malignancies that express the CD30 protein have been the scourge of oncologists for decades.…
#NewsBeep #News #Health #CA #Canada #cancer #CARTcells #GlobalGoodNews #healthnews #InnovationNews #Lymphoma #MedicalGoodNews #research #Science #t-cells #Technology
https://www.newsbeep.com/ca/191330/ -
Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!
Their work stands as a shining example of how research excellence can translate into real-world impact!
-
Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!
Their work stands as a shining example of how research excellence can translate into real-world impact!
-
Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!
Their work stands as a shining example of how research excellence can translate into real-world impact!
-
Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!
Their work stands as a shining example of how research excellence can translate into real-world impact!
-
Congratulations to Prof. Dr. Carl June & Prof. Dr. Michel Sadelain on receiving the 2025 Broermann Medical Innovation Award for the development of the CAR-T cell immunotherapy!
Their work stands as a shining example of how research excellence can translate into real-world impact!
-
In München und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. @InsertCaffeine erklärt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
-
In München und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. @InsertCaffeine erklärt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
-
In München und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. @InsertCaffeine erklärt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
-
In München und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. @InsertCaffeine erklärt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
-
In München und Singapur werkelt das #Startup Eximmium an neuen Antikörpern gegen #Krebs – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. @InsertCaffeine erklärt uns das Ganze genauer: https://www.laborjournal.de/editorials/3231.php #Biotech #CarTCells #Antikörper
-
'A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities -
'A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities -
'A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities -
'A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and there were no plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce'
#Immunotherapy #Immunology #CARTcells
https://www.fiercebiotech.com/biotech/caribou-cuts-nk-cell-therapy-program-lays-12-staff-fund-car-t-priorities -
'Twenty-nine different Car-T treatments for autoimmune diseases, ranging from the muscle inflammation condition myositis to multiple sclerosis, are now being tested in clinical trials by drugmakers including Novartis and Bristol Myers Squibb'
#Immunology #Autoimmunity #CARTcells
https://www.ft.com/content/a974f4c1-bb8a-4a1b-9d88-a2cf14be5c6e
-
'Twenty-nine different Car-T treatments for autoimmune diseases, ranging from the muscle inflammation condition myositis to multiple sclerosis, are now being tested in clinical trials by drugmakers including Novartis and Bristol Myers Squibb'
#Immunology #Autoimmunity #CARTcells
https://www.ft.com/content/a974f4c1-bb8a-4a1b-9d88-a2cf14be5c6e
-
'Twenty-nine different Car-T treatments for autoimmune diseases, ranging from the muscle inflammation condition myositis to multiple sclerosis, are now being tested in clinical trials by drugmakers including Novartis and Bristol Myers Squibb'
#Immunology #Autoimmunity #CARTcells
https://www.ft.com/content/a974f4c1-bb8a-4a1b-9d88-a2cf14be5c6e
-
'Twenty-nine different Car-T treatments for autoimmune diseases, ranging from the muscle inflammation condition myositis to multiple sclerosis, are now being tested in clinical trials by drugmakers including Novartis and Bristol Myers Squibb'
#Immunology #Autoimmunity #CARTcells
https://www.ft.com/content/a974f4c1-bb8a-4a1b-9d88-a2cf14be5c6e
-
'These studies have helped to answer “some of the questions that were precipitated by the FDA announcement,” Maus said. They still have not found definitive evidence that CAR-T therapy has directly caused new cancers, she said, and scientists continue to suspect that such an event would be extremely rare.'
#Immunology #Immunotherapy #CARTcells
https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss -
'These studies have helped to answer “some of the questions that were precipitated by the FDA announcement,” Maus said. They still have not found definitive evidence that CAR-T therapy has directly caused new cancers, she said, and scientists continue to suspect that such an event would be extremely rare.'
#Immunology #Immunotherapy #CARTcells
https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss -
'These studies have helped to answer “some of the questions that were precipitated by the FDA announcement,” Maus said. They still have not found definitive evidence that CAR-T therapy has directly caused new cancers, she said, and scientists continue to suspect that such an event would be extremely rare.'
#Immunology #Immunotherapy #CARTcells
https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss -
'These studies have helped to answer “some of the questions that were precipitated by the FDA announcement,” Maus said. They still have not found definitive evidence that CAR-T therapy has directly caused new cancers, she said, and scientists continue to suspect that such an event would be extremely rare.'
#Immunology #Immunotherapy #CARTcells
https://www.statnews.com/2024/07/12/cancer-car-t-therapy-fda-secondary-cancers/?utm_campaign=rss -
'Even without exposure to antigens, some CARs increase proliferation and nutrient uptake in T cells. Using stable isotope tracers and mass spectrometry, we observed basal metabolic fluxes through glycolysis doubling and amino acid uptake overtaking anaplerosis in CAR-T cells harbouring a rituximab scFv, unlike other similar anti-CD20 scFvs.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s42255-024-01034-7 -
'Even without exposure to antigens, some CARs increase proliferation and nutrient uptake in T cells. Using stable isotope tracers and mass spectrometry, we observed basal metabolic fluxes through glycolysis doubling and amino acid uptake overtaking anaplerosis in CAR-T cells harbouring a rituximab scFv, unlike other similar anti-CD20 scFvs.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s42255-024-01034-7 -
'Even without exposure to antigens, some CARs increase proliferation and nutrient uptake in T cells. Using stable isotope tracers and mass spectrometry, we observed basal metabolic fluxes through glycolysis doubling and amino acid uptake overtaking anaplerosis in CAR-T cells harbouring a rituximab scFv, unlike other similar anti-CD20 scFvs.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s42255-024-01034-7 -
'Even without exposure to antigens, some CARs increase proliferation and nutrient uptake in T cells. Using stable isotope tracers and mass spectrometry, we observed basal metabolic fluxes through glycolysis doubling and amino acid uptake overtaking anaplerosis in CAR-T cells harbouring a rituximab scFv, unlike other similar anti-CD20 scFvs.'
#Immunology #Immunotherapy #CARTcells
https://www.nature.com/articles/s42255-024-01034-7 -
'However, the established use of viral vectors for genetic engineering of CAR immune cells is still subject to particular safety concerns and requires further improvements. 1 Consequently, non-viral methods for immune cell engineering are gaining increasing interest. In this context, transposon-based technologies represent a promising alternative engineering technology that enables safe genomic insertions of large cargo, such as multi-cistronic CAR-expression cassettes, using fast and cost-effective manufacturing processes '
#Immunology #Immunotherapy #CARTcells
https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(24)00325-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001624003253%3Fshowall%3Dtrue -
'However, the established use of viral vectors for genetic engineering of CAR immune cells is still subject to particular safety concerns and requires further improvements. 1 Consequently, non-viral methods for immune cell engineering are gaining increasing interest. In this context, transposon-based technologies represent a promising alternative engineering technology that enables safe genomic insertions of large cargo, such as multi-cistronic CAR-expression cassettes, using fast and cost-effective manufacturing processes '
#Immunology #Immunotherapy #CARTcells
https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(24)00325-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001624003253%3Fshowall%3Dtrue -
'However, the established use of viral vectors for genetic engineering of CAR immune cells is still subject to particular safety concerns and requires further improvements. 1 Consequently, non-viral methods for immune cell engineering are gaining increasing interest. In this context, transposon-based technologies represent a promising alternative engineering technology that enables safe genomic insertions of large cargo, such as multi-cistronic CAR-expression cassettes, using fast and cost-effective manufacturing processes '
#Immunology #Immunotherapy #CARTcells
https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(24)00325-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001624003253%3Fshowall%3Dtrue -
'However, the established use of viral vectors for genetic engineering of CAR immune cells is still subject to particular safety concerns and requires further improvements. 1 Consequently, non-viral methods for immune cell engineering are gaining increasing interest. In this context, transposon-based technologies represent a promising alternative engineering technology that enables safe genomic insertions of large cargo, such as multi-cistronic CAR-expression cassettes, using fast and cost-effective manufacturing processes '
#Immunology #Immunotherapy #CARTcells
https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(24)00325-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001624003253%3Fshowall%3Dtrue -
" The insights derived from this analysis do not only support a CD19 CAR T cell-mediated reset of the memory B cell compartment, but also the parallel inhibition of the interferon signature
in #monocytes and #Tcells of #SLE patients"https://insight.jci.org/articles/view/179433
Striking that this apparently works better in getting rid of certain memory #Bcells than anti-CD20 antibodies.
-
" The insights derived from this analysis do not only support a CD19 CAR T cell-mediated reset of the memory B cell compartment, but also the parallel inhibition of the interferon signature
in #monocytes and #Tcells of #SLE patients"https://insight.jci.org/articles/view/179433
Striking that this apparently works better in getting rid of certain memory #Bcells than anti-CD20 antibodies.
-
" The insights derived from this analysis do not only support a CD19 CAR T cell-mediated reset of the memory B cell compartment, but also the parallel inhibition of the interferon signature
in #monocytes and #Tcells of #SLE patients"https://insight.jci.org/articles/view/179433
Striking that this apparently works better in getting rid of certain memory #Bcells than anti-CD20 antibodies.